Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE-005: SBRT in Oligometastatic Breast or Lung Cancer
NCT03808337Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2019
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression Free Survival at 2 years. Started Jan 2019; status: recruiting.
02
Conditions
breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03808337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808337.